By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ArrayIt today said that it has signed an agreement with Docro to assist in its efforts to win US Food and Drug Administration clearance for its OvaDx test.

ArrayIt's OvaDx is a pre-symptomatic ovarian cancer test that includes 100 proteomic biomarkers in a microarray format. The Sunnyvale, Calif.-based firm said that the test can detect both early- and late-stage ovarian cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: methylation patterns in multiple myeloma, recent Y chromosome bottleneck, and more.

By studying the spectra of microbes on Earth, a team of researchers hopes to be better equipped to detect any on other worlds.

SolveBio's Mark Kaganovich says at TechCrunch that genomics needs an app to push it into the mainstream.

A University of Michigan team is using a Facebook app to recruit and keep in touch with participants in its 'Genes for Good' project.